Medline Files for U.S. IPO, Citing Strong Growth, Market Rebound

Medical supply corporation Medline has filed for an initial public offering (IPO) in the U.S., following a strong financial performance in the first half of 2025. The company reported a 9.7% increase in net sales, reaching $13.53 billion, and a rise in profit to $655 million, compared to $587 million in the same period last year. Lukas Muehlbauer, research associate at IPOX, suggests the IPO indicates a continued openness in the IPO market. He emphasizes that Medline's performance will serve as a significant indicator of investor confidence, impacting the broader market into 2026, not solely the healthcare sector. Reuters reports the offering could value Medline at approximately $50 billion and potentially generate $5 billion in capital. The IPO represents a potentially lucrative outcome for private equity firms Blackstone, Carlyle, and Hellman & Friedman, who acquired Medline in 2021 for $34 billion.